Peginterferon plus ribavirin and sustained virological response rate in HCV-related advanced fibrosis: a real life study

Peginterferon plus ribavirin and sustained virological response rate in HCV-related advanced fibrosis: a real life study

Author Silva, Giovanni Faria Google Scholar
Villela-nogueira, Cristiane A. Google Scholar
Mello, Carlos Eduardo Brandao Google Scholar
Soares, Elza Cotrim Google Scholar
Coelho, Henrique Sergio M. Google Scholar
Ferreira, Paulo Roberto Abrão Autor UNIFESP Google Scholar
Ruiz, Fernando Jose Goes Google Scholar
Institution Universidade Estadual Paulista (UNESP)
Universidade Federal do Rio de Janeiro
Universidade Estadual de Campinas (UNICAMP)
Universidade Federal de São Paulo (UNIFESP)
Pontificia Universidade Catolica de São Paulo
Abstract Background: Tolerance and response to antiviral HCV treatment is poor in advanced fibrosis. The aim of this study was to assess SVR rate and its predictive factors in HCV advanced fibrosis patients treated in real life with full dose PEG-IFN plus RBV and to evaluate the adverse events related to treatment. Methods: A multicentric, retrospective study was conducted at six university hospitals. METAVIR F3 and F4 HCV monoinfected patients who were treated with PEG-IFN and RBV had their data analyzed. A stepwise logistic regression analysis was performed to identify the variables independently related to SVR. Adverse events were recorded during treatment. Results: 308 patients were included, 75% genotype 1 and 23% genotype 3. METAVIR F3 was present in 39% and F4 in 61% of patients. The median Child Pugh score for F4 patients was 5 (5–9). The global SVR rate was 34%, 11% were relapsers and 55% were nonresponders. SVR rates were similar between patients treated with PEG-IFN alfa 2a or alfa 2b (p = 0.24). SVR rates according to Child–Pugh score were 26% (Child A) and 18% (Child B). The independent factors related to SVR in F4 patients were genotype 3, RVR and fewer Child Pugh score points. Treatment interruption occurred in 31% patients and death occurred in 1.9%, all with liver cirrhosis. Conclusion: Treatment of HCV in patients with advanced fibrosis should not be postponed. However, a very careful evaluation of cirrhotic patients must be performed before treatment is indicated and careful monitoring is required during treatment.
Keywords Hepatitis C
Advanced fibrosis
Peginterferon
Ribavirin
Language English
Date 2014-01-01
Published in Brazilian Journal of Infectious Diseases. Brazilian Society of Infectious Diseases, v. 18, n. 1, p. 48-52, 2014.
ISSN 1413-8670 (Sherpa/Romeo, impact factor)
Publisher Brazilian Society of Infectious Diseases
Extent 48-52
Origin http://dx.doi.org/10.1016/j.bjid.2013.05.007
Access rights Open access Open Access
Type Article
Web of Science ID WOS:000332911100008
SciELO ID S1413-86702014000100048 (statistics in SciELO)
URI http://repositorio.unifesp.br/handle/11600/8202

Show full item record




File

Name: S1413-86702014000100048.pdf
Size: 624.1Kb
Format: PDF
Description:
Open file

This item appears in the following Collection(s)

Search


Browse

Statistics

My Account